Acumen Pharmaceuticals, Inc. financial data

Symbol
ABOS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
427 Park St., Charlottesville, VA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.3K % +8.02%
Debt-to-equity 12.6 % +192%
Return On Equity -24.6 % +2.84%
Return On Assets -21.9 % +10%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.1M shares +3.82%
Common Stock, Shares, Outstanding 60.1M shares +46.4%
Entity Public Float 134M USD -0.89%
Common Stock, Value, Issued 6K USD +50%
Weighted Average Number of Shares Outstanding, Basic 60.1M shares +46.4%
Weighted Average Number of Shares Outstanding, Diluted 60.1M shares +46.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 56.5M USD +53%
General and Administrative Expense 20.2M USD +31.9%
Operating Income (Loss) -76.7M USD -46.8%
Nonoperating Income (Expense) 11.8M USD +106%
Net Income (Loss) Attributable to Parent -64.9M USD -39.5%
Earnings Per Share, Basic -1.11 USD/shares +2.63%
Earnings Per Share, Diluted -1.11 USD/shares +2.63%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 68M USD
Marketable Securities, Current 193M USD +185%
Other Assets, Current 405K USD +94.7%
Assets, Current 267M USD +78.5%
Property, Plant and Equipment, Net 105K USD -22.8%
Operating Lease, Right-of-Use Asset 325K USD +1021%
Other Assets, Noncurrent 425K USD +104%
Assets 289M USD +62.9%
Accounts Payable, Current 4.21M USD +108%
Employee-related Liabilities, Current 1.84M USD +34.9%
Accrued Liabilities, Current 4M USD +68.7%
Liabilities, Current 15.4M USD +80.1%
Operating Lease, Liability, Noncurrent 219K USD
Liabilities 45M USD +427%
Accumulated Other Comprehensive Income (Loss), Net of Tax -164K USD +74.6%
Retained Earnings (Accumulated Deficit) -258M USD -33.5%
Stockholders' Equity Attributable to Parent 244M USD +44.5%
Liabilities and Equity 289M USD +62.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.9M USD -75.5%
Net Cash Provided by (Used in) Financing Activities 7.11M USD
Net Cash Provided by (Used in) Investing Activities -9.2M USD +78.1%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 60.1M shares +46.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 68.2M USD -11.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 756K USD
Deferred Tax Assets, Valuation Allowance 33.7M USD +52.2%
Deferred Tax Assets, Gross 34.1M USD +54%
Operating Lease, Liability 344K USD +228%
Depreciation 16K USD +14.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -64.4M USD -39.4%
Lessee, Operating Lease, Liability, to be Paid 388K USD
Operating Lease, Liability, Current 125K USD +331%
Lessee, Operating Lease, Liability, to be Paid, Year Two 158K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 155K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 44K USD +1000%
Lessee, Operating Lease, Liability, to be Paid, Year Three 158K USD
Deferred Tax Assets, Operating Loss Carryforwards 16.6M USD +26.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 38K USD -5%
Additional Paid in Capital 502M USD +38.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 437K USD +1357%
Share-based Payment Arrangement, Expense 8.19M USD +76.5%
Interest Expense 1M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%